Supernus Pharma (SUPN) Tops Q1 EPS by 16c, Beats on Revenues; Offers FY18 Revenue Mid-Point Outlook Below Consensus
Go back to Supernus Pharma (SUPN) Tops Q1 EPS by 16c, Beats on Revenues; Offers FY18 Revenue Mid-Point Outlook Below Consensus| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 44.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.48 | 52 Week High | $26.84 | |||
| Open | $44.69 | 52 Week Low | $9.51 | |||
| Day High | $45.50 | P/E | N/A | |||
| Day Low | $44.44 | EPS | $-2.62 | |||
| Volume | 544,635 | |||||

